Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD52 expression in mantle cell lymphoma.

Adam J Bass1, Jerald Gong, Ramona Nelson

  • 1Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA. ajb14@duke.edu

Leukemia & Lymphoma
|May 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level.

Haematologica·2026
Same author

Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.

Cancer·2026
Same author

PKMYT1 inhibition induces DNA damage and synergizes with immune checkpoint blockade in <i>CCNE1</i> -amplified gastroesophageal adenocarcinoma.

bioRxiv : the preprint server for biology·2025
Same author

Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Leukemia & lymphoma·2025
Same author

Exploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study.

Transplantation and cellular therapy·2025
Same author

Correction: High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Bone marrow transplantation·2025
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Mantle cell lymphoma is challenging to treat. However, tumor cells in mantle cell lymphoma express the CD52 antigen, suggesting that CAMPATH-1H therapy may be effective for these patients.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma with limited treatment options.
  • CAMPATH-1H (alemtuzumab) is a monoclonal antibody effective in other B-cell malignancies like chronic lymphocytic leukemia.

Purpose of the Study:

  • To investigate the expression of the CD52 antigen in mantle cell lymphoma tumor samples.
  • To evaluate the potential of CAMPATH-1H as a therapeutic agent for mantle cell lymphoma.

Main Methods:

  • Analysis of mantle cell lymphoma patient tumor samples.
  • Immunohistochemical detection of CD52 antigen expression.

Main Results:

  • Mantle cell lymphoma tumor cells were found to express the CD52 antigen.

Related Experiment Videos

  • This expression suggests susceptibility to CAMPATH-1H therapy.

    • Conclusions:

    • The CD52 antigen is present on mantle cell lymphoma cells.
    • CAMPATH-1H warrants further investigation as a potential treatment for mantle cell lymphoma.